27 May 2021

GSK v Teva Is the Future of Skinny Labelling to be Reconsidered

Skinny labelling has long allowed generic drugs to be approved for non-patented indications, allowing them to enter the market before the brand-name drug’s patent for other indications expires. In the recent GSK v Teva lawsuits, skinny labelling did not protect Teva from patent infringement and $235 million in damages.

Join us as we analyse the case and discuss the potential impact it will have on both brand and generic drug manufacturers. The session will include:

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk